A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 Regal AML trial nears final analysis, with 72 of 80 required survival events ...
Color us disappointed. With us, for thinking with our hearts instead of our minds and with Mercedes-Benz, for killing off what in just three years has become a legend. Indeed, ladies and gentlemen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results